Navigation Links
PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy

nd teachers reported that boys participating in the study had improvements in terms of greater activity level and increased endurance during treatment. Individual subjects at both dose levels demonstrated some improvements in upper and lower muscle strength however in the overall analysis the magnitude of change was not statistically significant.

PTC124 was well tolerated among the 26 patients included in the study. Adverse events were infrequent, mild to moderate in severity, and did not result in therapy interruptions or discontinuations. There were no safety concerns based on physical examinations, vital sign measurements, electrocardiograms or laboratory parameters. Compliance with PTC124 treatment was excellent at both dose levels.

Stuart W. Peltz, Ph.D., President and Chief Executive Officer of PTC Therapeutics, stated, "In addition to the clinical proof-of-concept data we disclosed late last year, these new insights provide us with further evidence supporting the potential of PTC124 in genetic disorders due to a nonsense mutation. The findings in the DMD trials are consistent with the results observed in Phase 2 clinical trials of PTC124 in patients with cystic fibrosis and with preclinical results in the DMD mouse model that were recently published in Nature. We are eager to extend testing of this concept into other nonsense-mediated genetic disorders."

About Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a progressive muscle disorder that causes the loss of both muscle function and independence. DMD is perhaps the most prevalent of the muscular dystrophies and is the most common lethal genetic disorder diagnosed during childhood today. Each year, approximately 20,000 children worldwide are born with DMD (one of every 3,500 male children). More information regarding DMD is available through the Muscular Dystrophy Association (www.mdausa.org) and the Parent Pro
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... the availability of the ResMed Data Exchange program, ... for home medical equipment (HME) and other health ... offers timely, secure access to critical patient information. ... from ResMed,s AirView™ and U-Sleep™ patient management platforms ...
(Date:10/20/2014)... --  BioNano Genomics announced today achievement of a major ... data at 30X depth, sufficient for a genome map, in ... established and demonstrated for the IrysChip TM V2, the ... and will be rolled out to BioNano,s collaborators and customers ... advancement at the American Society for Human Genetics (ASHG) ...
(Date:10/20/2014)... Oct. 20, 2014   Taiho Oncology, Inc. ... ( Japan ), announced that the ... Track designation for TAS-102 (nonproprietary names: trifluridine and ... investigation for the treatment of refractory metastatic colorectal ... a rolling NDA submission to the FDA. According ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
... Oct. 1 FASgen,s fatty acid synthase,inhibitor (FASi) ... solid tumor xenograft cell line tested, in both ... (H460; A549; H1975; LX7); two,ovarian; breast; and, colon. ... compounds have been shown in extensive preclinical studies ...
... Show Patients with Moderate to Severe Psoriasis Who Responded to, Anti-IL-12/23 ABT-874 ... ... 24 Weeks, BUENOS AIRES, Argentina, Oct. 1 ... Abbott,s,(NYSE: ABT ) investigational anti-IL-12/23 antibody ABT-874 showed that a,majority of ...
Cached Medicine Technology:FASgen Announces Significant Milestone in Its Cancer Drug Development Program 2Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 2Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 3Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 4
(Date:10/20/2014)... With a mere 19 days to ... a brief fundraising stop at the  Law Offices ... from a debate last night with his opponent Gov. ... the first seven minutes because Crist had an electric ... incident in one word: "weird." , Before touching on ...
(Date:10/20/2014)... 20, 2014 ASCNYC (ascnyc.org) is ... helps New Yorkers living with HIV/AIDS and other ... housing, recovery and self-sufficiency. Each year, ASCNYC spotlights ... community through their tireless efforts. , Savills ... , has been selected as this year’s honoree ...
(Date:10/20/2014)... IN (PRWEB) October 20, 2014 ... Start, a secure cloud solution that enables healthcare ... of the ultimate healthcare-specific customer relationship management (“CRM”) ... meet the unique needs of the healthcare industry, ... experience for providers and patients by combining healthcare ...
(Date:10/20/2014)... WA (PRWEB) October 20, 2014 My ... workflow management software application. The new module enables ... patients receive full life-cycle quality care. , This application ... others within their practice, attach a to-do item to ... fit, and even set up reoccurring reminders for follow-ups. ...
(Date:10/20/2014)... Myoderm announced today the ... their CentralSource service. Matthew will play ... drug sourcing, distribution, and management service for international ... of industry experience, in both business development and ... their international success to help clients manage their ...
Breaking Medicine News(10 mins):Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2
... , SAN FRANCISCO, CA February 2, 2010 -- ... coronary heart disease worldwide, only some obese individuals go ... relatively protected. Defining these protective factors could help scientists ... this end, a research team at the Gladstone Institute ...
... , , KNOXVILLE, Tenn. , ... TMH ), one of the largest suppliers of outsourced healthcare ... in the United States , today announced that the Company ... the market closes on Tuesday, February 9, 2010 , to ...
... , SAN DIEGO , Feb. 3 For ... the top 100 integrated health care networks in the nation in an ... was ranked No. 6 in the nation and No. 1 in ... Modern Healthcare , is regarded as the nation,s premier rating system for ...
... , , TUCSON, Ariz. , ... ) today announced that Fletcher McCusker , Chairman and Chief Executive ... the UBS 20th Annual Global Healthcare Services Conference on Wednesday, February ... .   , Providence ,s presentation is scheduled for 10:00 ...
... , ... FDA is alerting the public about the following products: , ... Alli, 60 mg capsules (120-count refill kit) sold over the Internet ... Insulin Syringes may have needles that detach from the syringe and ...
... , MT. LAUREL, N.J. , Feb. ... transcription software and services, today announced that it has agreed ... provider of clinical documentation technology and services that recently filed ... place pursuant to Section 363 of the United States Bankruptcy ...
Cached Medicine News:Health News:Gladstone scientists identify target that may reduce complications of obesity 2Health News:TeamHealth Holdings, Inc. Announces Fourth Quarter and Full Fiscal 2009 Earnings Release Date and Conference Call 2Health News:TeamHealth Holdings, Inc. Announces Fourth Quarter and Full Fiscal 2009 Earnings Release Date and Conference Call 3Health News:Sharp HealthCare Rated Top Health Care Network in California and No. 6 in the Nation 2Health News:Providence Service Corporation to Present at the UBS Global Healthcare Services Conference on Wednesday, February 10th 2Health News:Providence Service Corporation to Present at the UBS Global Healthcare Services Conference on Wednesday, February 10th 3Health News:FDA Consumer Health Information - FDA's MedWatch Safety Alerts: January 2010 2Health News:MedQuist Agrees to Purchase Domestic Assets of Spheris 2Health News:MedQuist Agrees to Purchase Domestic Assets of Spheris 3
Inquire...
... Calf Implants are available ... sizes. They are available non-sterile ... and sold individually. Depending on ... may use one or two ...
... the IQmark family elevates your ECG and Spirometry ... cost-savings and efficient patient care. The IQmark Diagnostic ... office, clinics and medical centers as well as ... in conjunction with the IQmark Digital ECG PDA ...
... data-gathering extension of the IQmark Diagnostic Workstation, ... Windows-based PC to deliver unmatched speed, accuracy ... Now you can download and seamlessly integrate ... simple click of a mouse. The point-and-click ...
Medicine Products: